Cue Biopharma Inc (NAS:CUE)
$ 1.56 -0.09 (-5.45%) Market Cap: 75.88 Mil Enterprise Value: 51.74 Mil PE Ratio: 0 PB Ratio: 2.52 GF Score: 52/100

Cue Biopharma, Inc. - Special Call Transcript

Mar 14, 2019 / 08:30PM GMT
Release Date Price: $7.16 (-1.92%)
Operator

Good afternoon, and welcome to Cue Biopharma's Quarterly Investor and Analyst Update Conference Call. (Operator Instructions) I will now turn the call over to John Woolford.

John Woolford
Westwicke Partners, LLC - MD

Good afternoon. This is John Woolford from Westwicke. Thank you for joining us on today's investor and analyst update call.

Joining me on the call today are Dan Passeri, Cue Biopharma's President and CEO; Dr. Anish Suri, Chief Scientific Officer; Dr. Ken Pienta, Acting Chief Medical Officer; and Kerri-Ann Millar, VP of Finance and Principal Accounting and Finance Officer. Also joining us on the call is Bethany Mancilla, our Chief Business Officer, who will be available for the Q&A section of the call. I want to note that a slide deck for today's call is available through the webcast in the Investors section of our website, www.cuebio.com.

Before we begin, I'd like to remind you that during today's call, the company will be making forward-looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot